Hugh James Freeman, MD, FRCPC, FACP, Series Editor

Venous thromboembolism with inflammatory bowel disease

Hugh James Freeman

Hugh James Freeman, Department of Medicine (Gastroenterology), University of British Columbia, Vancouver, BC, Canada

Author contribution: Freeman HJ contributed all to this paper.

Correspondence to: Dr. Hugh James Freeman, MD, FRCPC, FACP, Department of Medicine (Gastroenterology), University of British Columbia Hospital, 2211 Wesbrook Mall, Vancouver, BC V6T 1W5, Canada. hugfree@shaw.ca

Telephone: +1-604-8227216 Fax: +1-604-8227236

Received: December 4, 2007 Revised: January 3, 2008

Abstract

Venous thrombosis and thromboembolism appear to be increased in patients with inflammatory bowel disease. Although several acquired and genetic risk factors are known, about half that develop a thromboembolic event have no identifiable risk factor. Control of the inflammatory process is thought to be the key factor in risk reduction for thrombotic events. Prophylactic use of anticoagulants is not universally recommended, but possible use should be reviewed in an individual patient after evaluation of the risks, such as hemorrhage, compared to potential benefits. Particular consideration should be given if there has been a prior thrombotic event, if hospitalization will require surgery, or if an underlying coagulation disorder is present.

© 2008 WJG. All rights reserved.

Key words: Venous thrombosis; Thromboembolism; Inflammatory bowel disease; Crohn’s disease; Ulcerative colitis

Peer reviewer: Takayuki Yamamoto, MD, Inflammatory Bowel Disease Center, Yokkaichi Social Insurance Hospital, 10-8 Hazuyamacho, Yokkaichi, 510-0016, Japan

Freeman HJ. Venous thromboembolism with inflammatory bowel disease. World J Gastroenterol 2008; 14(7): 991-993 Available from: URL: http://www.wjgnet.com/1007-9327/14/991.asp DOI: http://dx.doi.org/10.3748/wjg.14.991

INTRODUCTION

Some studies[^1-5], but not all[^6], have suggested that there is a higher incidence of venous thrombosis and thromboembolism in the clinical course of inflammatory bowel disease, especially in hospitalized patients[^7]. In a population-based study[^3], the risk was estimated to be about three-fold. Moreover, thromboembolism appears to develop with inflammatory bowel disease at a younger age[^8]. Finally, thrombosis has also been reported in children with inflammatory bowel disease[^9].

ACQUIRED RISK FACTORS

Several risk factors have been hypothesized to contribute to development of thrombosis with inflammatory bowel disease. Some include the inflammatory process per se (with associated reactive thrombocytosis[^9]), prolonged immobilization, surgical treatment, fluid depletion, central venous catheters (often for nutritional support), hyperhomocysteinemia, vitamin deficiencies, smoking and use of oral contraceptives[^10]. Although hemostatic changes are frequent in inflammatory bowel disease patients, the precise reasons for thromboembolism during the course of inflammatory bowel disease are not known. Importantly, approximately half of the patients with inflammatory bowel disease that develop a thromboembolic event have no identifiable risk factor[^11].

A number of specific coagulation abnormalities have been recorded in patients with inflammatory bowel disease that may lead to a thromboembolic event. Increased levels of factors V, VII and VIII, lipoprotein(a) and fibrinogen, all risk factors for thrombosis, may occur. In addition, a reduction in natural anticoagulant factors including antithrombin III, protein C and protein S may develop[^12]. Homocysteinemia, another prothrombotic risk factor, may result from reduced folate, vitamin B6 or vitamin B12 levels. All of these vitamins may become deficient in patients with inflammatory bowel disease because of drug interference, impaired intake or malabsorption. To date, however, no consistent relationship with homocysteinemia and development of thromboembolism has been defined in patients with inflammatory bowel disease[^12-15]. Finally, changes associated with subclinical activation of the coagulation cascade[^14-16], along with diminished factor X III have been reported[^16,17].

GENETIC RISK FACTORS

Genetic factors may also play a role in patients with inflammatory bowel disease and have been reviewed elsewhere[^18]. Some may be more significant during remission or less active phases of inflammation[^19]. Factor V Leiden causes the activated form of factor V to be relatively resistant to degradation by activated protein C with
increased generation of thrombin. Factor V Leiden is often detected with venous thrombosis, but, to date, no difference between patients with inflammatory bowel disease and those without inflammatory bowel disease has been defined. In addition, a genetic variant of the prothrombin gene, G20210A, may be associated with deep venous thrombosis, but no definitive association between this gene mutation and inflammatory bowel disease has been detected. Also, a mutation in the methylenetetrahydrofolate reductase gene, C677T, may cause hyperhomocysteinemia but no differences have been detected between inflammatory bowel disease patients with thrombosis compared to controls with thrombosis. Finally, an inherited Val34Leu factor X III polymorphism has been found to be similar in inflammatory bowel disease compared to the general population.

MANAGEMENT OF THROMBOTIC RISK AND THROMBOSIS

The key to reduction of risk for thrombotic events in inflammatory bowel disease patients appears to be the control of the inflammatory process. Also, some of the medications used to treat ulcerative colitis and Crohn's disease may directly inhibit platelet activation. These include 5-aminosalicylic acid (5-ASA)-containing medications (eg, mesalazine, olsalazine) azathioprine and its metabolite, 6-mercaptopurine (6MP) and infliximab. Correction of altered nutrition and vitamin deficiencies is also important, especially if surgery and prolonged periods of immobilization are expected. Smoking should be discouraged and ongoing use of medications associated with increased thrombosis risk should be reviewed, specifically, oral contraceptives.

Use of prophylactic anticoagulation (eg, subcutaneous heparin) is not universally recommended, but should be considered on an individual patient basis after evaluation of the potential risks compared to the potential benefits of prophylaxis. In a New York series, the risk of death due to pulmonary embolism was recorded in a single patient after surgical treatment from among 1000 patients with Crohn's disease. Such information must be balanced by the potential risk of heparin treatment in inflammatory bowel disease, including the risk of hemorrhage. Certainly, a case can be made for prophylaxis if there has been a prior thrombotic or thromboembolic event, if the patient is hospitalized for surgery, or if an underlying inherited coagulation disorder is known to be present.

Heparin and drugs that specifically target platelets may play a role in the treatment of the inflammatory process per se owing to their anti-inflammatory properties, but their precise role needs further evaluation in clinical trials. If thrombosis does supervene during the course of inflammatory bowel disease, management should not be different from treatment of patients without inflammatory bowel disease. However, acquired risk factors should be minimized and exclusion of genetic defects, if tests are available, should be considered. Clearly, additional fundamental studies are needed to further elucidate the role of this inflammatory process and its mediators in the pathogenesis of thromboembolism followed by large multicenter clinical studies that might define the role of emerging treatments, including newer biologic therapies.

REFERENCES

1. Talbot RW, Heppell J, Dozois RR, Beart RW Jr. Vascular complications of inflammatory bowel disease. Mayo Clin Proc 1986; 61: 140-145
2. Solem CA, Loftus EV, Tremaine WJ, Sandborn WJ. Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol 2004; 99: 97-101
3. Bernstein CN, Blanchard JF, Houston DS, Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost 2001; 85: 430-434
4. Mielhser W, Reinsch W, Valic E, Osterode W, Tillinger W, Feichtenschlager T, Griser J, Machold K, Scholz S, Vogelsang H, Novacek G. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut 2004; 53: 542-548
5. Bernstein CN, Nabalamba A. Hospitalization-based major comorbidity of inflammatory bowel disease in Canada. Can J Gastroenterol 2007; 21: 507-511
6. Gosk-Bierska I, McBane RD, Waszczuk E, Paradowski L, Wysokinski WE. Prevalence of lower extremity venous disease in inflammatory bowel disease. Int Angiol 2007; 26: 67-71
7. Grip O, Svensson PJ, Lindgren S. Inflammatory bowel disease promotes venous thrombosis earlier in life. Scand J Gastroenterol 2000; 35: 619-623
8. Paradis K, Bernstein ML, Adelson JW. Thrombosis as a complication of inflammatory bowel disease in children: a report of four cases. J Pediatr Gastroenterol Nutr 1985; 4: 659-662
9. Danese S, Motte Cd Cde L, Fiocchi C. Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications. Am J Gastroenterol 2004; 99: 938-945
10. Danese S, Papa A, Saibeni S, Repici A, Malesci A, Vecchi M. Inflammation and coagulation in inflammatory bowel disease: The clot thickens. Am J Gastroenterol 2007; 102: 174-186
11. Jackson LM, O’Gorman PJ, O’Connell J, Cronin CC, Cotter KP, Shanahan F. Thrombosis in inflammatory bowel disease: clinical setting, procoagulant profile and factor V Leiden. JQJM 1997; 90: 183-188
12. Oldenburg B, Fijnheer R, van der Griend R, van Berge-Henegouwen GP, Koningsberger JC. Homocysteine in inflammatory bowel disease: a risk factor for thromboembolic complications? Am J Gastroenterol 2000; 95: 2825-2830
13. Romagnuolo J, Fedorov RA, Dias VC, Bamsforth F, Teitelso M. Hyperhomocysteinemia and inflammatory bowel disease: prevalence and predictors in a cross-sectional study. Am J Gastroenterol 2001; 96: 2143-2149
14. Souto JC, Martinez E, Roca M, Mateo J, Pujol J, Gonzalez D, Fontcuberta J. Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease. Dig Dis Sci 1995; 40: 1883-1889
15. Vecchi M, Cattaneo M, de Franchis R, Mannucci PM. Risk of thromboembolic complications in patients with inflammatory bowel disease. Study of hemostasis measurements. Int J Clin Lab Res 1991; 21: 165-170
16. Chamouard P, Grunebaum L, Wiesel ML, Frey PL, Wittenswer C, Sapin R, Baumann R, Cazenave JP. Prothrombin fragment 1 + 2 and thrombin-antithrombin III complex as markers of activation of blood coagulation in inflammatory bowel diseases. Eur J Gastroenterol Hepatol 1995; 7: 1183-1188
17. Lorenz R, Albert P, Born P. Factor XIII in chronic inflammatory bowel diseases. Semin Thromb Hemost 1996; 22: 451-455
18. Papa A, Danese S, Grillo A, Gabarrini G, Gabarrini A. Review article: inherited thrombophilia in inflammatory bowel disease. Am J Gastroenterol 2003; 98: 1247-1251
19. Spina L, Saibeni S, Battaglioni T, Peyvandi F, de Franchis R, Vecchi M. Thrombosis in inflammatory bowel diseases: role of inherited thrombophilia. Am J Gastroenterol 2005; 100: 2036-2041
20. Helio T, Wartiovaara U, Halme L, Turunen UM, Mikkola H, Palotie A, Farkkila M, Kontula K. Arg506Gln factor V mutation and Val34Leu factor XIII polymorphism in Finnish patients with inflammatory bowel disease. Scand J Gastroenterol 1999; 34: 170-174
21 Saibeni S, Vecchi M, Faioni EM, Franchi F, Rondonotti E, Borsi G, de Franchis R. Val34Leu factor XIII polymorphism in Italian patients with inflammatory bowel disease. *Dig Liver Dis* 2003; 35: 32-36

22 Carty E, MacEy M, Rampton DS. Inhibition of platelet activation by 5-aminosalicylic acid in inflammatory bowel disease. *Aliment Pharmacol Ther* 2000; 14: 1169-1179

23 Thomas G, Skrinska VA, Lucas FV. The influence of glutathione and other thiols on human platelet aggregation. *Thromb Res* 1986; 44: 859-866

24 Hommes DW, van Dullemen HM, Levi M, van der Ende A, Woody J, Tytgat GN, van Deventer SJ. Beneficial effect of treatment with a monoclonal anti-tumor necrosis factor-alpha antibody on markers of coagulation and fibrinolysis in patients with active Crohn's disease. *Haemostasis* 1997; 27: 269-277

25 Mendelsohn RR, Korelitz BI, Gleim GW. Death from Crohn's disease. Lessons from a personal experience. *J Clin Gastroenterol* 1995; 20: 22-26

26 Panes J, Esteve M, Cabre E, Hinojosa J, Andreu M, Sans M, Fernandez-Banares F, Feu F, Gassull MA, Pique JM. Comparison of heparin and steroids in the treatment of moderate and severe ulcerative colitis. *Gastroenterology* 2000; 119: 903-908

27 Papa A, Danese S, Gasbarrini A, Gasbarrini G. Review article: potential therapeutic applications and mechanisms of action of heparin in inflammatory bowel disease. *Aliment Pharmacol Ther* 2000; 14: 1403-1409

28 Tytgat GN, Van Nueten L, Van De Velde I, Joslyn A, Hanauer SB. Efficacy and safety of oral ridogrel in the treatment of ulcerative colitis: two multicentre, randomized, double-blind studies. *Aliment Pharmacol Ther* 2002; 16: 87-99

S- Editor Li DL   L- Editor Wang XL   E- Editor Liu Y